Robert J. Havey Institute for Global Health, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
Division of Infectious Diseases, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, United States of America.
PLoS One. 2024 Aug 5;19(8):e0302338. doi: 10.1371/journal.pone.0302338. eCollection 2024.
SARS-CoV-2 vaccines are safe and effective against infection and severe COVID-19 disease worldwide. Certain co-morbid conditions cause immune dysfunction and may reduce immune response to vaccination. In contrast, those with co-morbidities may practice infection prevention strategies. Thus, the real-world clinical impact of co-morbidities on SARS-CoV-2 infection in the recent post-vaccination period is not well established. This study was performed to understand the epidemiology of Omicron breakthrough infection and evaluate associations with number of comorbidities in a vaccinated and boosted population.
A retrospective clinical cohort study was performed utilizing the Northwestern Medicine Enterprise Data Warehouse. Our study population was identified as fully vaccinated adults with at least one booster. The primary risk factor of interest was the number of co-morbidities. The primary outcome was the incidence and time to the first positive SARS-CoV-2 molecular test in the Omicron predominant era. Multivariable Cox modeling analyses to determine the hazard of SARS-CoV-2 infection were stratified by calendar time (Period 1: January 1 -June 30, 2022; Period 2: July 1 -December 31, 2022) due to violations in the proportional hazards assumption. In total, 133,191 patients were analyzed. During Period 1, having 3+ comorbidities was associated with increased hazard for breakthrough (HR = 1.16 CI 1.08-1.26). During Period 2 of the study, having 2 comorbidities (HR = 1.45 95% CI 1.26-1.67) and having 3+ comorbidities (HR 1.73, 95% CI 1.51-1.97) were associated with increased hazard for Omicron breakthrough. Older age was associated with decreased hazard in Period 1 of follow-up. Interaction terms for calendar time indicated significant changes in hazard for many factors between the first and second halves of the follow-up period.
Omicron breakthrough is common with significantly higher risk for our most vulnerable patients with multiple co-morbidities. Age plays an important role in breakthrough infection with the highest incidence among young adults, which may be due to age-related behavioral factors. These findings reflect real-world differences in immunity and exposure risk behaviors for populations vulnerable to COVID-19.
SARS-CoV-2 疫苗在全球范围内对感染和严重 COVID-19 疾病均安全有效。某些合并症会导致免疫功能障碍,并可能降低疫苗接种后的免疫反应。相比之下,患有合并症的患者可能会采取感染预防策略。因此,最近接种疫苗后合并症对 SARS-CoV-2 感染的真实世界临床影响尚未得到充分确立。本研究旨在了解 Omicron 突破性感染的流行病学,并评估其与接种和加强针人群中合并症数量的关联。
本研究使用西北医学企业数据仓库进行了回顾性临床队列研究。我们的研究人群被确定为至少接种过一剂加强针的完全接种成年人。主要关注的风险因素是合并症的数量。主要结局是在 Omicron 为主的时期内首次 SARS-CoV-2 分子检测阳性的发生率和时间。由于违反比例风险假设,多变量 Cox 模型分析用于按日历时间(第 1 期:2022 年 1 月 1 日至 6 月 30 日;第 2 期:2022 年 7 月 1 日至 12 月 31 日)分层确定 SARS-CoV-2 感染的危险。总共分析了 133191 名患者。在第 1 期,有 3 种或以上合并症与突破性感染的风险增加相关(HR=1.16,95%CI 1.08-1.26)。在研究的第 2 期,有 2 种合并症(HR=1.45,95%CI 1.26-1.67)和 3 种或以上合并症(HR 1.73,95%CI 1.51-1.97)与 Omicron 突破性感染的风险增加相关。在随访的第 1 期,年龄较大与风险降低相关。日历时间的交互项表明,在随访的前半段和后半段之间,许多因素的风险都发生了显著变化。
Omicron 突破性感染很常见,患有多种合并症的高危患者感染风险显著增加。年龄在突破性感染中起着重要作用,在年轻成年人中发病率最高,这可能是由于与年龄相关的行为因素所致。这些发现反映了 COVID-19 易感染人群在免疫和暴露风险行为方面的真实世界差异。